

Trodelvy
Effective 01/01/2021

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Trodelvy is an antibody drug conjugate antineoplastic agent indicated for the treatment of metastatic or refractory triple-negative breast cancer in adults who have received 2 or more prior therapies for metastatic disease

Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with Trodelvy, excluding when the product is obtained as samples or via manufacturer's patient assistance program
OR

Approval of Trodelvy will be granted if the member meets all following criteria and documentation has been submitted:

1. The member has been diagnosed with metastatic triple-negative breast cancer
2. The prescriber is an oncologist or medication is being used in consultation with an oncologist.
3. The member has had an inadequate response or adverse reaction to at least two prior therapies for metastatic disease

Limitations

Initial approvals and reauthorizations will be granted at 12-month intervals.

References

1. Trodelvy (sacituzumab govitecan-hziy) [prescribing information]. Morris Plains, NJ: Immunomedics Inc; April 2020.

2. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. *N Engl J Med*. 2019;380(8):741-751. doi:10.1056/NEJMoa1814213 [\[PubMed 30786188\]](#)

Review History

11/18/2020- Reviewed at P+T. Effective 1/1/21.

